Lexeo Therapeutics (LXEO) Chardan's 8th Annual Genetic Medicines Conference summary

Clinical pipeline overview

• Three clinical-stage gene therapy programs target genetic cardiac diseases and APOE4-associated Alzheimer's, with near-term data readouts expected for all three programs.

• Friedreich's ataxia program focuses on cardiac pathology, showing reductions in left ventricular mass index (LVMI), wall thickness, and troponin, with a 14% reduction in wall thickness and 11.4% reduction in LVMI in the latest cohort.

• Arrhythmogenic cardiomyopathy (PKP2) program addresses a large unmet need, with preclinical models showing reversal of mortality and reduction of arrhythmias; early clinical readouts will focus on safety and biodistribution.

• APOE4 Alzheimer's program delivers the APOE2 gene to E4 homozygotes, with an imminent data readout to assess APOE2 expression and impact on key biomarkers like amyloid and tau.

• Manufacturing uses a high-yield Sf9 cell line platform, supporting commercial-scale production for both cardiac and CNS indications.

Friedreich's ataxia program details

• Therapy targets cardiac hypertrophy, the main mortality driver in FA, and is envisioned to complement existing neurologic therapies.

• Clinical data show meaningful improvements: 50% reduction in troponin, 14% in wall thickness, and 11.4% in LVMI, surpassing clinically meaningful thresholds.

• Study design includes a broad patient spectrum, supporting potential to treat early and advanced FA cardiomyopathy.

• LVMI is considered the most validated endpoint for pivotal studies due to its correlation with mortality.

• Regulatory update on surrogate endpoints and pivotal study design expected this year.

Arrhythmogenic cardiomyopathy (PKP2) program

• Targets a 60,000-patient rare disease with no approved therapies, offering a substantial commercial opportunity.

• Preclinical data show restored desmosomal function, reduced arrhythmias, and improved survival in murine models.

• Early clinical trial includes two dose cohorts, with cardiac biopsies and efficacy biomarkers (e.g., PVCs) collected.

• Initial readouts will emphasize safety and biodistribution, with efficacy signals expected to evolve over time.

• Differentiation from competitors may arise from vector serotype and expression/safety profiles, but clinical data will be decisive.